Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Charest, US

Alain Charest, Boston, MA US

Patent application numberDescriptionPublished
20100100974Models of Malignant Brain Cancer, and Therapeutic siRNAs Against Oncogenic Signaling Pathways, and Methods and Kits for Uses Therefor - Methods for screening compounds to treat an oncological disorder regulated through a tumor-inducing pathway are provided. The compounds are administered to non-human animal subjects having a disease model, so that the subjects display pathology symptoms that correspond to the oncological disorder in humans. The subjects carry a regulatable transgene expression, of which is associated with tumor formation, and further carry regulatable genes for suppression of tumor formation. The disease-pathology symptoms are induced using a site-specific recombination system to induce expression of the transgene associated with tumor formation and negatively regulate or eliminate the genes for suppression of the tumor formation. The methods further involve analyzing tumor formation in subjects administered the compound and comparing appearance and amount of tumors in the subjects administered the compound with control subjects not administered the compound. Also included are a vector for engineering a disease model and a kit for its use.04-22-2010

Alain Charest US

Patent application numberDescriptionPublished
20090098551METHODS AND PRODUCTS RELATED TO GENOTYPING AND DNA ANALYSIS - The invention encompasses methods and products related to genotyping. The method of genotyping of the invention is based on the use of single nucleotide polymorphisms (SNPs) to perform high throughput genome scans. The high throughput method can be performed by hybridizing SNP allele-specific oligonucleotides and a reduced complexity genome (RCG). The invention also relates to methods of preparing the SNP specific oligonucleotides and RCGs, methods of fingerprinting, determining allele frequency for a SNP, characterizing tumors, generating a genomic classification code for a genome, identifying previously unknown SNPs, and related compositions and kits.04-16-2009

Joseph Charest, Cambridge, MA US

Patent application numberDescriptionPublished
20110082563MICROSCALE MULTIPLE-FLUID-STREAM BIOREACTOR FOR CELL CULTURE - Microfluidic bioreactor devices may feature intercommunicating microchannels defined in two polymer layers separated by a membrane. A geometric parameter associated with the microchannels in one layer may vary along a length of those channels.04-07-2011

Joseph L. Charest, Cambridge, MA US

Patent application numberDescriptionPublished
20110155667Microfluidic Device for Blood Dialysis - The invention provides microfluidic devices and methods of using such devices for filtering solutions, such as blood.06-30-2011
20110158847Microfluidic Device Facilitating Gas Exchange, and Methods of Use and Manufacture Thereof - The invention provides systems and methods for exchanging gas in a microfluidic device, and methods for preparing such microfluidic devices. The systems and methods can be used to transfer oxygen to blood to assist lung function in a patient.06-30-2011

Leonard Charest, Redmond, WA US

Patent application numberDescriptionPublished
20100241603POLICY PROCESSOR FOR CONFIGURATION MANAGEMENT - A policy processor is described that may be used to implement a system for managing the configuration of assets in a distributed computing network, such as an enterprise network. The policy processor resides on a managed node in the distributed computing network and operates to receive, evaluate and enact policies issued by one or more policy authorities in the distributed computing network. The policy processor utilizes a conflict resolution model to determine which policy rules included within the policies should be put into effect and which should not.09-23-2010

Mark G. Charest, Belle Mead, NJ US

Patent application numberDescriptionPublished
20110009371SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF - The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.01-13-2011

Mark G. Charest, Cambridge, MA US

Patent application numberDescriptionPublished
20080242658Inhibitors of Iap - Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula I10-02-2008
20110015232Pyrrolydine Derivatives as IAP Inhibitors - The present invention relates to novel IAP inhibitor compounds of: Formula (I).01-20-2011
20110065726Organic Compounds - The present invention is directed to a compound of the formula:03-17-2011

Patent applications by Mark G. Charest, Cambridge, MA US

Pascale Charest, San Diego, CA US

Patent application numberDescriptionPublished
20090123953Double brilliance beta-arrestin: a biosensor for monitoring the activity of receptors and signalling molecules, and method of using same - An intramolecular bioluminescence resonance energy transfer (BRET), biosensor for monitoring receptor activity and signalling cascades is disclosed. The “double-brilliance” biosensor sandwiches β-arrestin (β-arr) between Renilla 05-14-2009

Robert Charest, Orlando, FL US

Patent application numberDescriptionPublished
20110125593ONLINE MARKETING PAYMENT MONITORING METHOD AND SYSTEM - A method of collecting and correlating information about user interactions with a plurality of websites including adding a first cookie from a first website, the first cookie recording information concerning interactions of a user with the first website; adding a second cookie from a second website, the second cookie recording information concerning interactions of the user with the second website; initiating a tracking pixel on a third website; capturing information from the first and second cookie; and determining a first contribution of the first website and a second contribution of the second website to interests in the third website.05-26-2011